(Q46624251)

23 December 2017

title

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose (English)

1 reference

23 December 2017

0 references

Hans O Hallander

1

1 reference

23 December 2017

Lennart Gustafsson

series ordinal

2

1 reference

23 December 2017

Margaretha Ljungman

series ordinal

3

1 reference

23 December 2017

Jann Storsaeter

series ordinal

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

46-47

1 reference

23 December 2017

page(s)

5359-5364

1 reference

23 December 2017

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Recent progress in clinical and basic pertussis research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Whooping cough--a continuing problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

European Sero-Epidemiology Network: standardisation of the assay results for pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Antibodies to pertussis antigens in pediatric health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Pasteur Merieux Connaught five-component acellular pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Outcomes of Bordetella pertussis infection in different age groups of an immunized population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunoge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.06.009

1 reference

23 December 2017

1 reference

23 December 2017